Logo

Sanofi's Dupixent (dupilumab) Receives European Commission Approval for Severe Asthma with Type 2 Inflammation

Share this

Sanofi's Dupixent (dupilumab) Receives European Commission Approval for Severe Asthma with Type 2 Inflammation

Shots:

  • The approval is based on LIBERTY ASTHMA program including two P-III (QUEST and VENTURE) & one P-IIb studies assessing Dupixent + SOC vs PBO in 2-888 adults and adolescents aged 12+ in patients with severe asthma + type 2 inflammation- characterized by raised blood eosinophils and/or fractional exhaled nitric oxide
  • Results in patients with eosinophils ≥300 cells/µliter & FeNO levels ≥25 parts/billion: reduction in severe exacerbations (67% & 65%); Improvement in lung function- @12wks. improvement in FEV1 (33% vs 16% & 30% vs 14%) (26% vs 10%)- reduction in oral corticoid use @24wks. (70% vs 42%)
  • Dupixent (dupilumab-200mg & 300mg) is a biologic- targeting IL-4 & IL-13- marketed as a pre-filled syringe and has received EU’s & FDA approval for moderate-to-severe atopic dermatitis & asthma respectively

Ref: Sanofi | Image: The Economic Times

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions